RAC1突变黑色素瘤的特征与结局
研究纳入迄今最大RAC1突变黑色素瘤患者集(n=64),包括埃森大学医院回顾性单中心队列(n=34)和TRIM前瞻性多中心队列(n=30),分析患者与肿瘤特征及治疗结局。RAC1突变见于约2%的测序样本(64/3037),以P29S最常见(95%,61/64),多数合并MAP激酶突变(88%,56/64)。晚期患者接受免疫检查点抑制剂(ICI)治疗可获益。
要点
- RAC1突变见于约2%的测序黑色素瘤样本(64/3037),P29S占95%(61/64)。
- 88%(56/64)的RAC1突变肿瘤合并MAP激酶突变,以NRAS激活突变最常见(47%,30/64)。
- III/IV期患者一线治疗客观缓解率为21%,中位总生存期为47.8个月。
核心结论
- RAC1突变黑色素瘤罕见,多起源于皮肤,常合并MAP激酶突变尤其是NRAS突变。
- 晚期患者可从ICI全身治疗中获益。
研究设计与样本
- 研究纳入迄今最大的RAC1突变黑色素瘤患者集(n=64)。
- 包括埃森大学医院回顾性单中心队列(n=34)和TRIM前瞻性多中心队列(n=30)。
- 分析患者与肿瘤特征及治疗结局。
主要发现
- 3037例测序样本中RAC1突变约占2%(64/3037)。
- 最常见RAC1突变为P29S(95%,61/64)。
- 88%(56/64)的肿瘤合并MAP激酶突变:NRAS激活突变47%(30/64)、BRAF激活突变28%(18/64)、NF1突变25%(16/64)。
- RAC1突变黑色素瘤几乎均为皮肤原发(84%,54/64)或原发灶不明(14%,9/64)。
- C>T改变是最常见突变类型,提示紫外线特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Activating hot spot R29S mutations in RAC1, a small GTPase influencing several cellular processes including cell proliferation and cytoskeleton rearrangement, have been reported in up to 9% of sun-exposed melanomas. Clinical characteristics and treatment implications of RAC1 mutations in melanoma remain unclear. METHODS: We investigated the largest set (n = 64) of RAC1 mutated melanoma patients reported to date, including a retrospective single institution cohort (n = 34) from the University Hospital Essen and a prospective multicentre cohort (n = 30) from the translational study Tissue Registry in Melanoma (TRIM; CA209-578), for patient and tumour characteristics as well as therapy outcomes. RESULTS: From 3037 sequenced melanoma samples screened RAC1 mutations occurred in ∼2% of samples (64/3037). The most common RAC1 mutation was P29S (95%, 61/64). The majority of tumours had co-occuring MAP kinase mutations (88%, 56/64); mostly activating NRAS (47%, 30/64) mutations, followed by activating BRAF (28%, 18/64) and NF1 (25%, 16/64) mutations. RAC1 mutated melanomas were almost exclusively of cutaneous origin (84%, 54/64) or of unknown primary (MUP, 14%, 9/64). C > T alterations were the most frequent mutation type identified demonstrating a UV-signature for RAC1 mutated melanoma. Most patients with unresectable disease (39) received immune checkpoint inhibitors (ICI) (77%, 30/39). Objective response rate of first-line treatment in patients with stage III/IV disease was 21%; median overall survival was 47.8 months. CONCLUSIONS: RAC1 mutated melanomas are rare, mostly of cutaneous origin and frequently harbour concomitant MAP kinase mutations, particularly in NRAS. Patients with advanced disease benefit from systemic treatment with ICI.
引用
- Lodde GC, Jansen P, Herbst R, et al. Characterisation and outcome of RAC1 mutated melanoma. Eur J Cancer. 2023. PMID: 36773463. doi:10.1016/j.ejca.2023.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。